Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Challenges of international oncology trial collaboration-a call to action|
|Citation:||British Journal of Cancer, 2019; 121(7):515-521|
|Monica Tang, Heikki Joensuu, Robert J. Simes, Timothy J. Price, Sonia Yip, Wendy Hague, Katrin M. Sjoquist and John Zalcberg|
|Abstract:||International collaboration in oncology trials has the potential to enhance clinical trial activity by expediting the recruitment of large patient populations, testing treatments in diverse populations and facilitating the study of rare tumours or specific molecular subtypes. However, a number of challenges continue to hinder the efficient and productive conduct of both commercial and non-commercial international clinical trials. These challenges include complex and burdensome regulatory requirements, the high cost of conducting trials, and logistical challenges associated with ethics review, drug supply and biospecimen collection and management. We propose solutions to promote oncology trial collaboration, such as regulatory reform, harmonisation of trial initiation and management processes and greater recognition and funding of academic (non-commercial) clinical trials. It is only through coordinated effort and leadership from researchers, regulators and those responsible for health systems that the full potential of international trial collaboration can be realised.|
|Keywords:||Cancer; drug development; research management|
|Rights:||© The Author(s), under exclusive licence to Cancer Research UK 2019. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.